JP4101876B2 - 抗炎症活性を有する脂質抽出物 - Google Patents

抗炎症活性を有する脂質抽出物 Download PDF

Info

Publication number: JP4101876B2
Authority: JP; Japan
Prior art keywords: composition; treatment; oil; lipid extract; inflammatory
Prior art date: 1995-09-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP51149997A

Other languages

English (en)

Japanese (ja)

Other versions

JPH11512400A5 (2

JPH11512400A (ja

Inventor

マークライズ，セオドア

カラファティス，ニコレット

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmalink International Ltd

Original Assignee

Pharmalink International Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-11

Filing date

1996-09-10

Publication date

2008-06-18

1996-09-10 Application filed by Pharmalink International Ltd filed Critical Pharmalink International Ltd

1999-10-26 Publication of JPH11512400A publication Critical patent/JPH11512400A/ja

2004-09-16 Publication of JPH11512400A5 publication Critical patent/JPH11512400A5/ja

2008-06-18 Application granted granted Critical

2008-06-18 Publication of JP4101876B2 publication Critical patent/JP4101876B2/ja

2016-09-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000284 extract Substances 0.000 title claims description 34
150000002632 lipids Chemical class 0.000 title claims description 32
230000003110 anti-inflammatory effect Effects 0.000 title claims description 27
239000000203 mixture Substances 0.000 claims description 41
238000011282 treatment Methods 0.000 claims description 32
206010003246 arthritis Diseases 0.000 claims description 25
239000004480 active ingredient Substances 0.000 claims description 21
239000007788 liquid Substances 0.000 claims description 14
239000004006 olive oil Substances 0.000 claims description 14
235000008390 olive oil Nutrition 0.000 claims description 14
241001465754 Metazoa Species 0.000 claims description 13
238000000194 supercritical-fluid extraction Methods 0.000 claims description 13
241001537210 Perna Species 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 8
239000003921 oil Substances 0.000 claims description 8
235000019198 oils Nutrition 0.000 claims description 8
239000003961 penetration enhancing agent Substances 0.000 claims description 6
229960005233 cineole Drugs 0.000 claims description 5
239000003981 vehicle Substances 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 4
229930007050 cineol Natural products 0.000 claims description 3
239000010776 emu oil Substances 0.000 claims description 2
229940087305 limonene Drugs 0.000 claims description 2
235000001510 limonene Nutrition 0.000 claims description 2
239000006210 lotion Substances 0.000 claims description 2
239000002674 ointment Substances 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
125000003555 cineol group Chemical group 0.000 claims 1
241000237536 Mytilus edulis Species 0.000 description 25
235000020638 mussel Nutrition 0.000 description 19
241000700159 Rattus Species 0.000 description 17
238000012360 testing method Methods 0.000 description 17
230000000694 effects Effects 0.000 description 16
238000003556 assay Methods 0.000 description 14
238000009472 formulation Methods 0.000 description 14
238000000034 method Methods 0.000 description 14
238000000605 extraction Methods 0.000 description 12
210000002683 foot Anatomy 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 11
241001537211 Perna canaliculus Species 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
206010030113 Oedema Diseases 0.000 description 8
239000000679 carrageenan Substances 0.000 description 8
235000010418 carrageenan Nutrition 0.000 description 8
229940113118 carrageenan Drugs 0.000 description 8
229920001525 carrageenan Polymers 0.000 description 8
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 8
230000001154 acute effect Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
206010036030 Polyarthritis Diseases 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
230000003111 delayed effect Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
208000030428 polyarticular arthritis Diseases 0.000 description 6
239000000126 substance Substances 0.000 description 6
241000700157 Rattus norvegicus Species 0.000 description 5
230000002917 arthritic effect Effects 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000005995 Aluminium silicate Substances 0.000 description 4
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
102000008186 Collagen Human genes 0.000 description 4
108010035532 Collagen Proteins 0.000 description 4
WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
229960001138 acetylsalicylic acid Drugs 0.000 description 4
235000012211 aluminium silicate Nutrition 0.000 description 4
230000002456 anti-arthritic effect Effects 0.000 description 4
229920001436 collagen Polymers 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000002904 solvent Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000003501 anti-edematous effect Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
-1 free fatty acids Chemical class 0.000 description 3
210000000548 hind-foot Anatomy 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000008176 lyophilized powder Substances 0.000 description 3
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000000346 nonvolatile oil Substances 0.000 description 3
238000011020 pilot scale process Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000000638 solvent extraction Methods 0.000 description 3
230000008961 swelling Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
230000001754 anti-pyretic effect Effects 0.000 description 2
239000002221 antipyretic Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
235000008524 evening primrose extract Nutrition 0.000 description 2
229940089020 evening primrose oil Drugs 0.000 description 2
239000010475 evening primrose oil Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
210000004744 fore-foot Anatomy 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
231100000420 gastrotoxicity Toxicity 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000341 volatile oil Substances 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
208000036487 Arthropathies Diseases 0.000 description 1
206010012186 Delayed delivery Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
229940124346 antiarthritic agent Drugs 0.000 description 1
229940124347 antiarthritic drug Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000001387 apium graveolens Substances 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940009100 aurothiomalate Drugs 0.000 description 1
XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
150000001840 cholesterol esters Chemical class 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
UGOFYAXVVVXMQT-UHFFFAOYSA-N clobuzarit Chemical compound C1=CC(COC(C)(C)C(O)=O)=CC=C1C1=CC=C(Cl)C=C1 UGOFYAXVVVXMQT-UHFFFAOYSA-N 0.000 description 1
229950007550 clobuzarit Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000249 desinfective effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
206010013990 dysuria Diseases 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
235000013402 health food Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 description 1
229950000752 methylhexaneamine Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000010464 refined olive oil Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003902 salicylic acid esters Chemical class 0.000 description 1
229940119224 salmon oil Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
230000036620 skin dryness Effects 0.000 description 1
229960001315 sodium aurothiomalate Drugs 0.000 description 1
239000011343 solid material Substances 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dermatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Zoology (AREA)
Marine Sciences & Fisheries (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

JP51149997A 1995-09-11 1996-09-10 抗炎症活性を有する脂質抽出物 Expired - Lifetime JP4101876B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AU5311		1995-09-11
AUPN5311A AUPN531195A0 (en)	1995-09-11	1995-09-11	Lipid extract having anti-inflamatory activity
PCT/AU1996/000564 WO1997009992A1 (en)	1995-09-11	1996-09-10	Lipid extract having anti-inflammatory activity

Publications (3)

Publication Number	Publication Date
JPH11512400A JPH11512400A (ja)	1999-10-26
JPH11512400A5 JPH11512400A5 (2)	2004-09-16
JP4101876B2 true JP4101876B2 (ja)	2008-06-18

Family

ID=3789640

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP51149997A Expired - Lifetime JP4101876B2 (ja)	1995-09-11	1996-09-10	抗炎症活性を有する脂質抽出物

Country Status (12)

Country	Link
US (2)	US6083536A (2)
EP (1)	EP0850068B1 (2)
JP (1)	JP4101876B2 (2)
AT (1)	ATE293984T1 (2)
AU (1)	AUPN531195A0 (2)
CA (1)	CA2231803C (2)
DE (1)	DE69634666T2 (2)
DK (1)	DK0850068T3 (2)
ES (1)	ES2241001T3 (2)
PT (1)	PT850068E (2)
WO (1)	WO1997009992A1 (2)
ZA (1)	ZA967626B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20220131272A (ko)	2020-01-21	2022-09-27	린트벨스 리미티드	상승효과가 있는 조성물

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPN531195A0 (en) *	1995-09-11	1995-10-05	J.W. Broadbent Nominees Pty. Ltd.	Lipid extract having anti-inflamatory activity
US6479277B2 (en)	1997-06-04	2002-11-12	Cellular Improvements Ltd.	Method and apparatus for disruption of biological material
SE9703085D0 (sv) *	1997-08-27	1997-08-27	Micro Active Protein In Sweden	Anti-microbial composition
US6946144B1 (en)	1998-07-08	2005-09-20	Oryxe	Transdermal delivery system
US7220427B2 (en)	1998-07-08	2007-05-22	Oryxe	Mixture for transdermal delivery of low and high molecular weight compounds
DE19838794A1 (de) *	1998-08-26	2000-03-09	Aristavet Veterinaerspezialita	Zusammensetzung zur Behandlung von Osteoarthritis und zur nutritiven Behandlung des Gelenkknorpels
AUPP910699A0 (en) *	1999-03-10	1999-04-01	Pharmalink International Limited	Inhibitor of lipoxygenase pathways
US6596303B1 (en) *	1999-03-22	2003-07-22	Mars Incorporated	Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals
AU2005200953B2 (en) *	1999-03-22	2007-07-12	Mars, Incorporated	Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same
US20020018787A1 (en) *	1999-05-21	2002-02-14	Roger V. Kendall	Methods and compositions for modulating immune response and for the treatment of inflammatory disease
DE60038320D1 (de) *	1999-07-21	2008-04-24	Bomac Research Ltd	Mittel zur bekämpfung von entzündungen und/oder degenerativen erkrankungen
DE60012026T2 (de) *	1999-08-26	2004-12-30	Ganeden Biotech, Inc., San Diego	Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
AUPR030800A0 (en)	2000-09-22	2000-10-12	Pharmalink International Limited	Immunomodulatory preparation
AU2001293477B2 (en) *	2000-09-22	2006-05-18	Pharmalink International Limited	Immunomodulatory preparation
US7519546B2 (en) *	2001-04-30	2009-04-14	General Electric Company	Maintaining synchronization of information published to multiple subscribers
EP1417211B1 (en)	2001-07-27	2007-05-30	Neptune Technologies & Bioressources Inc.	Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses
AUPS082102A0 (en) *	2002-03-01	2002-03-21	Women's And Children's Hospital	Therapeutic properties of oils
WO2003077811A1 (en) *	2002-03-14	2003-09-25	Mcclung Jackie H	Pharmaceutically active compounds containing phosphorous defficient oil
DE20210182U1 (de) *	2002-07-01	2002-10-02	Bio-Innovation Development Ltd., Christchurch	Wirkstoffzusammensetzung aus Bestandteilen der Grünlippenmuschel (perna canaliculus) und zusätzlichen Omega-3-Fettsäuren
EP1603405A4 (en) *	2003-03-14	2006-05-24	Foodscience Corp	METHOD FOR THE TREATMENT OF CANCER WITH PERNA CANALICULUS INGREDIENTS (EN) AND PERNA CANALICULUS EXTRACTS
US7052715B2 (en) *	2003-04-11	2006-05-30	All Natural Fmg, Inc.	Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
US7033998B2 (en) *	2003-04-11	2006-04-25	All Natural Fmg, Inc.	Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
US7572464B2 (en) *	2004-01-30	2009-08-11	Bionovate Limited	Solvent extraction of lipids such as essential fatty acids
GB0411165D0 (en) *	2004-05-19	2004-06-23	Bionovate Ltd	Hyaluronic acid containing pharmaceutical or veterinary compounds
GB0411166D0 (en) *	2004-05-19	2004-06-23	Bionovate Ltd	Treatment for asthma and arthritis
US20060039992A1 (en) *	2004-06-02	2006-02-23	Miller Bruce A Jr	Novel compositions and methods utilizing green-lipped mussel and fatty acids
WO2006052150A1 (en) *	2004-11-15	2006-05-18	University Of Otago	Mussel extract composition with enhanced anti-inflammatory activity
US8092839B2 (en) *	2004-12-13	2012-01-10	Swing Aerobics Licensing, Inc.	Medicament for treatment of cancer and other diseases
US8431165B2 (en) *	2004-12-13	2013-04-30	Swing Aerobics Licensing, Inc.	Medicament for treatment of cancer and other diseases
NZ563125A (en) *	2005-06-03	2009-11-27	Mcfarlane Marketing Aust Pty L	Lipid extract of mussels and method for preparation thereof
NZ547429A (en) *	2006-05-24	2009-09-25	Ind Res Ltd	Extraction of highly unsaturated lipids with liquid dimethyl ether
US20090221703A1 (en)	2006-07-09	2009-09-03	Chongxi Yu	High penetration composition and uses thereof
US20090238763A1 (en)	2006-07-09	2009-09-24	Chongxi Yu	High penetration compositions and uses thereof
CA2657636C (en)	2006-07-18	2021-11-09	Techfields Biochem Co. Ltd	Positively charged water soluble prodrugs of ibuprofen with very fast skin penetration rate
CN101500982A (zh)	2006-07-25	2009-08-05	于崇曦	具有快速皮肤穿透速度的带正电荷的水溶性双氯芬酸前药
PL2049482T3 (pl)	2006-08-08	2016-04-29	Techfields Biochem Co Ltd	Dodatnio naładowane rozpuszczalne w wodzie proleki kwasów arylo- i heteroarylooctowych o bardzo dużej szybkości przenikania przez skórę
EP2084132B1 (en)	2006-09-03	2018-08-08	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
JP5466006B2 (ja)	2006-09-03	2014-04-09	テックフィールズバイオケムカンパニーリミテッド	非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
WO2008035756A1 (en) *	2006-09-22	2008-03-27	Heimat Co., Ltd.	Anti-angiogenic composition comprising extract having anti-angiogenic activity and lecithin
EP2781505A1 (en) *	2006-10-02	2014-09-24	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
CN101522692A (zh)	2006-10-11	2009-09-02	于崇曦	具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
NZ552238A (en)	2006-12-20	2009-07-31	Seperex Nutritionals Ltd	An extract
WO2008146298A1 (en) *	2007-06-01	2008-12-04	Ganga Raju Gokaraju	Use of aphanamixis polystacha extracts or fractions against 5 -lipoxygenase mediated diseases
WO2008149181A1 (en)	2007-06-04	2008-12-11	Techfields Inc	Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
MX340963B (es) *	2008-04-28	2016-07-29	Vermont Italia Srl	Formulacion farmaceutica que contiene palmitoil etanolamida y estearoil etanolamida.
RU2630577C2 (ru)	2008-12-04	2017-09-11	Чунси ЮЙ	Композиции интенсивного проникновения и их применение
JP5313064B2 (ja) *	2009-07-03	2013-10-09	株式会社ノエビア	中性脂肪蓄積促進剤、豊胸剤
ES2969344T3 (es)	2012-01-18	2024-05-17	Techfields Pharma Co Ltd	Composiciones de profármaco de alta penetración y composición farmacéutica del mismo para el tratamiento de afecciones pulmonares
SG11201505076UA (en)	2012-12-31	2015-07-30	Jrx Biotechnology Inc	Liquid topical pharmaceutical nano-emulsion formulations
JP6176655B2 (ja) *	2013-07-02	2017-08-09	御木本製薬株式会社	マトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤、老化防止用皮膚外用剤、シワ防止用皮膚外用剤、慢性関節リウマチ及び他の疾患の治療又は予防剤
AU2015402832B2 (en) *	2015-07-20	2022-06-02	Jiangyin Bengt I. Samuelsson Institute Of Life Science Co., Ltd.	Mussel adhesive protein product and applications thereof in suppression of skin inflammations
US11260018B2 (en)	2015-09-17	2022-03-01	Jrx Biotechnology, Inc.	Approaches for improving skin hydration and moisturization
US20200016215A1 (en) *	2016-12-20	2020-01-16	Sanford Limited	Bioactive mussel compositions and/or extracts
KR20200096593A (ko) *	2017-12-04	2020-08-12	림프로스트 테크놀로지스 에이에스	갑각류 어획물로부터 단백질 인지질 복합체를 제조하는 방법
WO2019123400A1 (en)	2017-12-22	2019-06-27	Pharmalink International Limited	Lipid combinations
US12604918B2 (en)	2020-01-21	2026-04-21	Lintbells Limited	Synergistic compositions
CN113041263B (zh) *	2021-03-15	2023-07-25	青岛大学	一种贻贝功能性脂质在制备治疗2型糖尿病产品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2965855D1 (en)	1978-09-25	1983-08-18	Farlane Stuart John Mc	Pharmaceutical preparations containing a mollusc extract
US4801453A (en) *	1984-05-01	1989-01-31	James M. Broadbent	Stabilized mussel extract
AUPM740594A0 (en)	1994-08-11	1994-09-01	J.W. Broadbent Nominees Pty. Ltd.	Anti-inflammatory preparation
AU3156595A (en) *	1994-08-11	1996-03-07	J.W. Broadbent Nominees Pty. Ltd.	Anti-inflammatory preparation
AUPN531195A0 (en) *	1995-09-11	1995-10-05	J.W. Broadbent Nominees Pty. Ltd.	Lipid extract having anti-inflamatory activity

1995
- 1995-09-11 AU AUPN5311A patent/AUPN531195A0/en not_active Abandoned
1996
- 1996-09-10 JP JP51149997A patent/JP4101876B2/ja not_active Expired - Lifetime
- 1996-09-10 CA CA002231803A patent/CA2231803C/en not_active Expired - Lifetime
- 1996-09-10 DE DE69634666T patent/DE69634666T2/de not_active Expired - Lifetime
- 1996-09-10 US US09/029,957 patent/US6083536A/en not_active Expired - Lifetime
- 1996-09-10 DK DK96929129T patent/DK0850068T3/da active
- 1996-09-10 EP EP96929129A patent/EP0850068B1/en not_active Expired - Lifetime
- 1996-09-10 ES ES96929129T patent/ES2241001T3/es not_active Expired - Lifetime
- 1996-09-10 ZA ZA9607626A patent/ZA967626B/xx unknown
- 1996-09-10 PT PT96929129T patent/PT850068E/pt unknown
- 1996-09-10 WO PCT/AU1996/000564 patent/WO1997009992A1/en not_active Ceased
- 1996-09-10 AT AT96929129T patent/ATE293984T1/de active
2000
- 2000-07-05 US US09/610,484 patent/US6346278B1/en not_active Expired - Lifetime

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20220131272A (ko)	2020-01-21	2022-09-27	린트벨스 리미티드	상승효과가 있는 조성물

Also Published As

Publication number	Publication date
US6083536A (en)	2000-07-04
CA2231803A1 (en)	1997-03-20
WO1997009992A1 (en)	1997-03-20
AUPN531195A0 (en)	1995-10-05
PT850068E (pt)	2005-08-31
DE69634666D1 (de)	2005-06-02
US6346278B1 (en)	2002-02-12
ATE293984T1 (de)	2005-05-15
CA2231803C (en)	2004-11-23
EP0850068A1 (en)	1998-07-01
EP0850068A4 (en)	2000-09-13
DK0850068T3 (da)	2005-08-15
ES2241001T3 (es)	2005-10-16
ZA967626B (en)	1997-09-03
EP0850068B1 (en)	2005-04-27
JPH11512400A (ja)	1999-10-26
DE69634666T2 (de)	2006-04-27

Legal Events

Date	Code	Title	Description
2007-08-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070828
2007-12-20	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071127
2008-01-21	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121
2008-01-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071227
2008-02-15	TRDD	Decision of grant or rejection written
2008-02-26	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080226
2008-03-27	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080321
2008-03-28	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3
2008-03-28	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2008-05-02	R154	Certificate of patent or utility model (reissue)	Free format text: JAPANESE INTERMEDIATE CODE: R154
2008-05-08	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3
2011-03-03	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3
2012-03-01	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20120328 Year of fee payment: 4
2012-03-06	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5
2013-02-28	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5
2013-03-05	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20140328 Year of fee payment: 6
2014-03-11	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-03-10	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-03-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-09-10	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
US6083536A (en)	2000-07-04	Super-critical lipid extract from mussels having anti-inflammatory activity
RU2122409C1 (ru)	1998-11-27	Лечение жирными кислотами
EP0440341B1 (en)	1993-12-08	EFA compositions and therapy
Gutiérrez et al.	2009	Hepatoprotective and inhibition of oxidative stress in liver of prostechea michuacana.
US4874794A (en)	1989-10-17	Inflammatory disease treatment
EP0189788B1 (de)	1989-09-13	Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
JPS61215322A (ja)	1986-09-25	γ‐リノレン酸またはジホモ‐γ‐リノレン酸の使用方法
NZ227241A (en)	1991-05-28	Pharmaceutical compositions comprising a cyclosporin and either dihomo-gamma or gamma-linolenic acid and use in combatting the effects of cyclosporin administration
US20140107206A1 (en)	2014-04-17	Omega-3 pentaenoic acid compositions and methods of use
EP0560806A1 (en)	1993-09-22	Anti-inflammatory composition derived from emu oil
EP0524796B1 (en)	1995-04-12	Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS
JPS6229511A (ja)	1987-02-07	ミクロエマルジヨン組成物
DE3907649C2 (de)	1996-07-11	Arzneimittel, geeignet bei der Bekämpfung von Viren und zur Immunstimulierung
JP2011067213A (ja)	2011-04-07	生物活性油
JPH04505758A (ja)	1992-10-08	即効で増強された解熱応答
AU616502B2 (en)	1991-10-31	Treatment of inflammatory disorders in humans
US5194451A (en)	1993-03-16	Systemic anti-inflammatory treatment
US5166219A (en)	1992-11-24	Systemic anti-inflammatory treatment
CN105407885A (zh)	2016-03-16	包含ω-3脂肪酸和番茄的番茄红素的组合
US20080274209A1 (en)	2008-11-06	Methods of treating inflammation
KR960700064A (ko)	1996-01-19	아연이 보충된 전립선 추출물
US5260067A (en)	1993-11-09	Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same
JP2018039769A (ja)	2018-03-15	ウロリチン類を含有する前駆脂肪細胞分化抑制剤
Schulz et al.	2004	Effects of acetylsalicylic acid on ascorbic acid concentrations in plasma, gastric mucosa, gastric juice and urine--a double-blind study in healthy subjects
AU703368B2 (en)	1999-03-25	Lipid extract having anti-inflammatory activity

JP4101876B2 - 抗炎症活性を有する脂質抽出物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (3)

Family

ID=3789640

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (57)

Family Cites Families (5)

Cited By (1)

Also Published As

Similar Documents

Legal Events